Literature DB >> 1874738

The chymotrypsin inhibitor carbobenzyloxy-leucine-tyrosine-chloromethylketone interferes with phospholipase D activation induced by formyl-methionyl-leucyl-phenylalanine in human neutrophils.

G C Kessels1, A Gervaix, P D Lew, A J Verhoeven.   

Abstract

The effects of carbobenzyloxy-leucine-tyrosine-chloromethylketone (zLYCK), an inhibitor of chymotrypsin-like proteases, on signal transduction in human neutrophils triggered by the chemoattractant formyl-methionyl-leucyl-phenylalanine (fMLP) were investigated. zLYCK (10 microM) inhibited the fMLP-induced respiratory burst in neutrophils treated with cytochalasin B. In the presence of zLYCK (10 microM), the activation of phospholipase D in response to fMLP addition was inhibited. zLYCK did not inhibit the binding of [3H] fMLP to its receptor or the enzymic activity of phospholipase D because the response to ionomycin was unaffected. The effect of zLYCK on phospholipase D correlated well with its effects on the accumulation of diglycerides, which was also inhibited in the presence of zLYCK. In electropermeabilized neutrophils, too, zLYCK caused an inhibition of the fMLP-induced respiratory burst and the fMLP-induced activation of phospholipase D. Interestingly, this inhibition could be bypassed by guanosine 5'-O-(thiotriphosphate). We conclude that the inhibition of the respiratory burst in human neutrophils by zLYCK is caused by the selective inhibition of signal transduction leading to activation of phospholipase D and that zLYCK might be a useful probe to study the role of phospholipase D in neutrophil activation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1874738

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Wheat germ agglutinin induces NADPH-oxidase activity in human neutrophils by interaction with mobilizable receptors.

Authors:  A Karlsson
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

2.  Phospholipase D-derived phosphatidic acid is involved in the activation of the CD11b/CD18 integrin in human eosinophils.

Authors:  A T Tool; M Blom; D Roos; A J Verhoeven
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

3.  Chromogenic assay for phospholipase D from Streptomyces chromofuscus: application to the evaluation of substrate analogs.

Authors:  P J Hergenrother; M K Haas; S F Martin
Journal:  Lipids       Date:  1997-07       Impact factor: 1.880

4.  Activation of phospholipase D is an early event in integrin-mediated signalling leading to phagocytosis in human neutrophils.

Authors:  L Serrander; M Fällman; O Stendahl
Journal:  Inflammation       Date:  1996-08       Impact factor: 4.092

5.  Inhibition of phospholipase D blocks activation of fibrinogen-adherent neutrophils by tumor necrosis factor.

Authors:  M O Frank; G W Sullivan; H T Carper; G L Mandell
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

6.  Protein kinase C activity is not involved in N-formylmethionyl-leucyl-phenylalanine-induced phospholipase D activation in human neutrophils, but is essential for concomitant NADPH oxidase activation: studies with a staurosporine analogue with improved selectivity for protein kinase C.

Authors:  G C Kessels; K H Krause; A J Verhoeven
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

7.  Cytosolic free calcium is essential for immunoglobulin G-stimulated intracellular killing of Staphylococcus aureus by human monocytes.

Authors:  L Zheng; P H Nibbering; R van Furth
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

8.  Inhibition of neutrophil chemotaxis by protease inhibitors. Differential effect of inhibitors of serine and thiol proteases.

Authors:  J B Barna; R R Kew
Journal:  Inflammation       Date:  1995-10       Impact factor: 4.092

9.  Roles of phospholipase D in phorbol myristate acetate-stimulated neutrophil respiratory burst.

Authors:  Tianhui Hu; Zhaoxia Liu; Xun Shen
Journal:  J Cell Mol Med       Date:  2011-03       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.